Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Spencer E McMinn

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Nature|September 1, 2022
Screening for generality in asymmetric catalysisCorin C Wagen, Spencer E McMinn, Eugene E Kwan, et al.
Nature|July 2, 2026
Author Correction: Synthesis of enantioenriched atropisomers by biocatalytic deracemizationCasey B Roos, S Luke Schulert, Lara E Zetzsche, et al.
Nature|November 12, 2025
Synthesis of enantioenriched atropisomers by biocatalytic deracemizationCasey B Roos, S Luke Schulert, Lara E Zetzsche, et al.
Biochemistry|October 21, 2024
High-Throughput Algorithmic Optimization of <i>In Vitro</i> Transcription for SARS-CoV-2 mRNA Vaccine ProductionSpencer E McMinn, Danielle V Miller, Daniel Yur, et al.
ACS Medicinal Chemistry Letters|November 19, 2021
Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase InhibitorsDerun Li, Hongjun Zhang, Thomas W Lyons, et al.
Journal of Medicinal Chemistry|February 12, 2026
Discovery and In Vivo Evaluation of Aryl Ether YAP1/TEAD Inhibitors for the Treatment of Hippo-Driven MalignanciesBrandon A Vara, Jongwon Lim, Casey J Moure, et al.
Journal of Medicinal Chemistry|March 30, 2026
Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's DiseaseElsie C Yu, Hua Zhou, Xin Yan, et al.
Journal of Medicinal Chemistry|April 27, 2026
Correction to "Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's Disease"Elsie C Yu, Hua Zhou, Xin Yan, et al.
Journal of Medicinal Chemistry|October 20, 2023
Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's DiseaseSolomon D Kattar, Anmol Gulati, Kaila A Margrey, et al.
Journal of Medicinal Chemistry|September 4, 2024
Discovery and Optimization of N-Heteroaryl Indazole LRRK2 InhibitorsKaitlyn M Logan, Will Kaplan, Vladimir Simov, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Nature|September 1, 2022
Screening for generality in asymmetric catalysisCorin C Wagen, Spencer E McMinn, Eugene E Kwan, et al.
Nature|July 2, 2026
Author Correction: Synthesis of enantioenriched atropisomers by biocatalytic deracemizationCasey B Roos, S Luke Schulert, Lara E Zetzsche, et al.
Nature|November 12, 2025
Synthesis of enantioenriched atropisomers by biocatalytic deracemizationCasey B Roos, S Luke Schulert, Lara E Zetzsche, et al.
Biochemistry|October 21, 2024
High-Throughput Algorithmic Optimization of <i>In Vitro</i> Transcription for SARS-CoV-2 mRNA Vaccine ProductionSpencer E McMinn, Danielle V Miller, Daniel Yur, et al.
ACS Medicinal Chemistry Letters|November 19, 2021
Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase InhibitorsDerun Li, Hongjun Zhang, Thomas W Lyons, et al.
Journal of Medicinal Chemistry|February 12, 2026
Discovery and In Vivo Evaluation of Aryl Ether YAP1/TEAD Inhibitors for the Treatment of Hippo-Driven MalignanciesBrandon A Vara, Jongwon Lim, Casey J Moure, et al.
Journal of Medicinal Chemistry|March 30, 2026
Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's DiseaseElsie C Yu, Hua Zhou, Xin Yan, et al.
Journal of Medicinal Chemistry|April 27, 2026
Correction to "Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's Disease"Elsie C Yu, Hua Zhou, Xin Yan, et al.
Journal of Medicinal Chemistry|October 20, 2023
Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's DiseaseSolomon D Kattar, Anmol Gulati, Kaila A Margrey, et al.
Journal of Medicinal Chemistry|September 4, 2024
Discovery and Optimization of N-Heteroaryl Indazole LRRK2 InhibitorsKaitlyn M Logan, Will Kaplan, Vladimir Simov, et al.
Pageof 2